Linagliptin
Chemical compound
Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. Linagliptin is a dipeptidyl peptidase-4 inhibitor that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. It is generally less preferred than metformin and sulfonylureas as an initial treatment. It is taken by mouth.
Common side effects include inflammation of the nose and throat. Serious side effects may include angioedema, pancreatitis, joint pain. Use in pregnancy and breastfeeding is not recommended.
Linagliptin was approved for medical use in the United States, Japan, the European Union, Canada, and Australia in 2011. In 2023, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions. From August 2021, linagliptin became available as a generic medicine in the US.
01Medical uses
Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
02Side effects
Linagliptin may cause severe joint pain.
03Mechanism of action
Linagliptin belongs to a class of drugs called DPP-4 inhibitors.
04Names
Linagliptin is the international nonproprietary name (INN). Brand names: Trajenta, Tradjenta.
Sources and credits
This article is adapted from the Wikipedia article “Linagliptin”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- Linagliptin.svg by Vaccinationist, Public domain
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.
